Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Obstructive Lung Diseases

Free Subscription Articles published in Eur Respir J Retrieve available abstracts of 291 articles: HTML format

Single Articles

April 2024
1. SPINOU A, Hererro-Cortina B, Aliberti S, Goeminne PC, et al
   Airway clearance management in people with bronchiectasis: data from the European Bronchiectasis Registry (EMBARC).
   Eur Respir J. 2024 Apr 12:2301689. doi: 10.1183/13993003.01689-2023.
   PubMed     Abstract available
   
   
   
2. HATTER L, Holliday M, Eathorne A, Bruce P, et al
   The carbon footprint of as-needed budesonide-formoterol in mild asthma: a post hoc analysis.
   Eur Respir J. 2024 Apr 12:2301705. doi: 10.1183/13993003.01705-2023.
   PubMed     Abstract available
   
   
   
3. JACKSON DJ, Pelaia G, Emmanuel B, Tran TN, et al
   Benralizumab in severe eosinophilic asthma by previous biologic use and key clinical subgroups: real-world XALOC-1 programme.
   Eur Respir J. 2024 Apr 4:2301521. doi: 10.1183/13993003.01521-2023.
   PubMed     Abstract available
   
   
   
4. COTTIN V
   Combined pulmonary fibrosis and emphysema syndrome: the age of majority.
   Eur Respir J. 2024;63:2400353.
   PubMed    
   
   
   
5. KRISHNAN JA, Buhl R
   As-needed ICS/formoterol or as-needed SABA in mild asthma?
   Eur Respir J. 2024;63:2302308.
   PubMed    
   
   
   
6. PAPI A, Ferreira DS, Tonia T, Schleich F, et al
   Response from the authors: As-needed ICS/formoterol or as-needed SABA in mild asthma?
   Eur Respir J. 2024;63:2400395.
   PubMed    
   
   
   
7. 
   "Therapeutic improvement of CFTR function and reversibility of bronchiectasis in cystic fibrosis." M.O. Wielputz and M.A. Mall. Eur Respir J 2024; 63: 2400234.
   Eur Respir J. 2024;63:2450234.
   PubMed    
   
   
   
8. TANG RD, Yue JQ, Guan WJ
   Sputum colour as a simplified effective biomarker for clinical assessment of bronchiectasis.
   Eur Respir J. 2024;63:2400152.
   PubMed    
   
   
   
9. STANESCU C, Talarico R, Weichenthal S, Villeneuve PJ, et al
   Early life exposure to pollens and increased risks of childhood asthma: a prospective cohort study in Ontario children.
   Eur Respir J. 2024;63:2301568.
   PubMed     Abstract available
   
   
   
10. ALIBERTI S, Ringshausen FC, Dhar R, Haworth CS, et al
    Objective sputum colour assessment and clinical outcomes in bronchiectasis: data from the European Bronchiectasis Registry (EMBARC).
    Eur Respir J. 2024;63:2301554.
    PubMed     Abstract available
    
    
    
11. VARRICCHI G, Brightling CE, Grainge C, Lambrecht BN, et al
    Airway remodelling in asthma and the epithelium: on the edge of a new era.
    Eur Respir J. 2024;63:2301619.
    PubMed     Abstract available
    
    
    March 2024
12. LIU T, Liu S, Rui X, Cao Y, et al
    Gasdermin B, an asthma-susceptibility gene, promotes MAVS-TBK1 signaling and airway inflammation.
    Eur Respir J. 2024 Mar 21:2301232. doi: 10.1183/13993003.01232-2023.
    PubMed     Abstract available
    
    
    
13. RUSSELL RJ, Boulet LP, Brightling CE, Pavord ID, et al
    The airway epithelium: an orchestrator of inflammation, a key structural barrier and a therapeutic target in severe asthma.
    Eur Respir J. 2024 Mar 7:2301397. doi: 10.1183/13993003.01397-2023.
    PubMed     Abstract available
    
    
    
14. JIN Z, Wang G
    Some future directions for genome-wide association studies of preserved ratio impaired spirometry.
    Eur Respir J. 2024;63:2400142.
    PubMed    
    
    
    
15. 
    "Asthma and incident coronary heart disease: an observational and Mendelian randomisation study." C.A. Valencia-Hernandez, F. Del Greco M, V. Sundaram, et al. Eur Respir J 2023; 62: 2301788.
    Eur Respir J. 2024;63:2351788.
    PubMed    
    
    
    
16. 
    "Aberrant anti-viral response of natural killer cells in severe asthma." J. Devulder, C. Chenivesse, V. Ledroit, et al. Eur Respir J 2020; 55: 1802422.
    Eur Respir J. 2024;63:1852422.
    PubMed    
    
    
    
17. WIELPUTZ MO, Mall MA
    Therapeutic improvement of CFTR function and reversibility of bronchiectasis in cystic fibrosis.
    Eur Respir J. 2024;63:2400234.
    PubMed    
    
    
    
18. BOS S, Murray J, Marchetti M, Cheng GS, et al
    ERS/EBMT clinical practice guidelines on treatment of pulmonary chronic graft-versus-host disease in adults.
    Eur Respir J. 2024;63:2301727.
    PubMed     Abstract available
    
    
    February 2024
19. BHATT SP, Bodduluri S, Nakhmani A
    ERS/ATS spirometry interpretation standards: a gap in grading severity of airflow obstruction.
    Eur Respir J. 2024;63:2301910.
    PubMed    
    
    
    
20. STANOJEVIC S, Kaminsky DA, Miller MR, Thompson B, et al
    Reply to: ERS/ATS spirometry interpretation standards: a gap in grading severity of airflow obstruction.
    Eur Respir J. 2024;63:2400055.
    PubMed    
    
    
    
21. WEBB AJ
    "Every beet you take": lowering systolic blood pressure and improving vascular function/exercise capacity via the dietary nitrate-nitrite-NO pathway in patients with COPD.
    Eur Respir J. 2024;63:2302238.
    PubMed    
    
    
    
22. ALASMARI AM, Alsulayyim AS, Alghamdi SM, Philip KEJ, et al
    Oral nitrate supplementation improves cardiovascular risk markers in COPD: ON-BC, a randomised controlled trial.
    Eur Respir J. 2024;63:2202353.
    PubMed     Abstract available
    
    
    
23. COHEN R, Shteinberg M
    Unravelling the "frequent exacerbator" phenotype in cystic fibrosis.
    Eur Respir J. 2024;63:2400068.
    PubMed    
    
    
    
24. WANG T, Duan W, Jia X, Huang X, et al
    Associations of combined phenotypic ageing and genetic risk with incidence of chronic respiratory diseases in the UK Biobank: a prospective cohort study.
    Eur Respir J. 2024;63:2301720.
    PubMed     Abstract available
    
    
    
25. VERLEDEN SE, Lapperre TS, Snoeckx A, Wen W, et al
    Interalveolar pore morphology in (pre-)COPD stages and associations with small airways.
    Eur Respir J. 2024;63:2302263.
    PubMed    
    
    
    
26. 
    ERJ Podcast February 2024: Beetroot juice and cardiovascular risk in COPD.
    Eur Respir J. 2024;63:24E6302.
    PubMed    
    
    
    January 2024
27. YOHANNES AM, Iyer AS, Hoth KF, Dransfield MT, et al
    Cognitive behavioural therapy sessions approach ineffective for anxiety and depression in COPD: is the door closed for good?
    Eur Respir J. 2024;63:2301857.
    PubMed    
    
    
    
28. TAYLOR SJC, Sohanpal R, Steed L, Marshall K, et al
    Reply: Cognitive behavioural therapy sessions approach ineffective for anxiety and depression in COPD: is the door closed for good?
    Eur Respir J. 2024;63:2302149.
    PubMed     Abstract available
    
    
    
29. HIGBEE DH, Lirio A, Hamilton F, Granell R, et al
    Genome-wide association study of preserved ratio impaired spirometry (PRISm).
    Eur Respir J. 2024;63:2300337.
    PubMed     Abstract available
    
    
    
30. ZHU Z
    Early-life airway microbiome and childhood asthma development.
    Eur Respir J. 2024;63:2302187.
    PubMed    
    
    
    
31. HOGMAN M, Bowerman C, Chavez L, Dressel H, et al
    ERS technical standard: Global Lung Function Initiative reference values for exhaled nitric oxide fraction (F (ENO(50)) ).
    Eur Respir J. 2024;63:2300370.
    PubMed     Abstract available
    
    
    
32. 
    ERJ Podcast January 2024: The microbiome in early life and childhood asthma.
    Eur Respir J. 2024;63:24E6301.
    PubMed    
    
    
    December 2023
33. SUNDE RB MD PHD, Thorsen J MD PhD, Kim M MSc PhD, Schoos AM MD PhD, et al
    Bacterial Colonization of the Airway in Neonates and Risk of Asthma and Allergy Until Age 18 Years.
    Eur Respir J. 2023 Dec 14:2300471. doi: 10.1183/13993003.00471-2023.
    PubMed     Abstract available
    
    
    
34. BEASLEY R, Noble J, Weatherall M
    Clinical remission with biologic therapies in severe asthma: a matter of definition.
    Eur Respir J. 2023;62:2301844.
    PubMed    
    
    
    
35. SUISSA S
    Simplifying pharmacotherapy for patients with COPD: a viewpoint.
    Eur Respir J. 2023;62:2301510.
    PubMed    
    
    
    
36. CELLI B, Vestbo J
    Reply: Simplifying pharmacotherapy for patients with COPD: a viewpoint.
    Eur Respir J. 2023;62:2301600.
    PubMed    
    
    
    
37. WECKMANN M, Reddy KD
    Epigenome-wide association studies: the exposures of yesterday form the methylations of tomorrow.
    Eur Respir J. 2023;62:2301552.
    PubMed    
    
    
    November 2023
38. ZHAO A, Gudmundsson E, Mogulkoc N, van Moorsel C, et al
    Mortality surrogates in combined pulmonary fibrosis and emphysema.
    Eur Respir J. 2023 Nov 16:2300127. doi: 10.1183/13993003.00127-2023.
    PubMed     Abstract available
    
    
    
39. CIVIDINI S, Sinha I, Donegan S, Maden M, et al
    Best step-up treatments for children with uncontrolled asthma: A systematic review and network meta-analysis of individual participant data.
    Eur Respir J. 2023 Nov 9:2301011. doi: 10.1183/13993003.01011-2023.
    PubMed     Abstract available
    
    
    
40. VALENCIA-HERNANDEZ CA, Del Greco M F, Sundaram V, Portas L, et al
    Asthma and incident coronary heart disease: an observational and Mendelian randomisation study.
    Eur Respir J. 2023 Nov 9:2301788. doi: 10.1183/13993003.01788-2023.
    PubMed     Abstract available
    
    
    
41. SORIANO JB, Polverino F
    Sex and gender in COPD and asthma.
    Eur Respir J. 2023;62:2301505.
    PubMed    
    
    
    
42. EVANS R, Doe G
    Can the curse of mood disorders in COPD be lifted and enable pulmonary rehabilitation?
    Eur Respir J. 2023;62:2301538.
    PubMed    
    
    
    
43. TAYLOR SJC, Sohanpal R, Steed L, Marshall K, et al
    Tailored psychological intervention for anxiety or depression in COPD (TANDEM): a randomised controlled trial.
    Eur Respir J. 2023;62:2300432.
    PubMed     Abstract available
    
    
    
44. NEPTUNE ER, Cardoso WV
    Unravelling the expanding role of FGF10 signalling in lung homeostasis and maintenance.
    Eur Respir J. 2023;62:2301691.
    PubMed    
    
    
    
45. MORGAN C, Higbee D
    An attack of asthma is not an attack of the heart: clarifying causal links between asthma and incident coronary heart disease.
    Eur Respir J. 2023;62:2302009.
    PubMed    
    
    
    October 2023
46. HADZIC S, Wu CY, Gredic M, Pak O, et al
    Fibroblast growth factor 10 reverses cigarette smoke- and elastase-induced emphysema and pulmonary hypertension in mice.
    Eur Respir J. 2023 Oct 26:2201606. doi: 10.1183/13993003.01606-2022.
    PubMed     Abstract available
    
    
    
47. MCDOWELL PJ, McDowell R, Busby J, Eastwood MC, et al
    Clinical remission in severe asthma with Biologic Therapy: an analysis from the UK Severe Asthma Registry.
    Eur Respir J. 2023 Oct 19:2300819. doi: 10.1183/13993003.00819-2023.
    PubMed     Abstract available
    
    
    
48. WANG KCW, Elliot JG, Saglani S, Donovan GM, et al
    The airway smooth muscle layer is structurally abnormal in low birth weight infants - implications for obstructive disease.
    Eur Respir J. 2023 Oct 12:2301176. doi: 10.1183/13993003.01176-2023.
    PubMed    
    
    
    
49. HERRERA-LUIS E, de la Rosa-Baez C, Huntsman S, Eng C, et al
    Novel insights into the whole blood DNA methylome of asthma in ethnically diverse children and youth.
    Eur Respir J. 2023 Oct 6:2300714. doi: 10.1183/13993003.00714-2023.
    PubMed     Abstract available
    
    
    
50. HERRERO-CORTINA B, Spinou A, Oliveira A, O'Neill B, et al
    Airway clearance techniques and exercise in people with bronchiectasis: two different coins.
    Eur Respir J. 2023;62:2300741.
    PubMed    
    
    
    
51. 
    October Podcast: ERS short guidelines for the use of as-needed ICS/formoterol in mild asthma.
    Eur Respir J. 2023;62:23E6204.
    PubMed    
    
    
    September 2023
52. FIOCCHI AG, Phipatanakul W, Zeiger RS, Durrani SR, et al
    Dupilumab leads to better-controlled asthma & quality of life in children: the VOYAGE study.
    Eur Respir J. 2023 Sep 21:2300558. doi: 10.1183/13993003.00558-2023.
    PubMed     Abstract available
    
    
    
53. PAPI A, Ferreira DS, Agache I, Baraldi E, et al
    European Respiratory Society Short Guidelines for the use of as-needed ICS/formoterol in mild Asthma.
    Eur Respir J. 2023 Sep 7:2300047. doi: 10.1183/13993003.00047-2023.
    PubMed     Abstract available
    
    
    
54. SINGH D
    GOLD 2023 streamlines pharmacological treatment.
    Eur Respir J. 2023;62:2301335.
    PubMed    
    
    
    
55. FARINHA I, Heaney LG
    Defining trajectory in severe asthma: can it be changed?
    Eur Respir J. 2023;62:2301281.
    PubMed    
    
    
    
56. SUISSA S
    Single-inhaler triple versus dual bronchodilator therapy for GOLD group E and other exacerbating patients with COPD: real-world comparative effectiveness and safety.
    Eur Respir J. 2023;62:2300883.
    PubMed    
    
    
    
57. HIEMSTRA PS, Heijink IH
    Oxidation alters IL-33 function: new insights in the biology of different forms of IL-33 and their relevance for COPD.
    Eur Respir J. 2023;62:2301301.
    PubMed    
    
    
    
58. AGUSTI A, Faner R
    All roads lead to COPD... or not?
    Eur Respir J. 2023;62:2301470.
    PubMed    
    
    
    
59. DIVO MJ, Liu C, Polverino F, Castaldi PJ, et al
    From pre-COPD to COPD: a Simple, Low cost and easy to IMplement (SLIM) risk calculator.
    Eur Respir J. 2023;62:2300806.
    PubMed     Abstract available
    
    
    
60. STRICKSON S, Houslay KF, Negri VA, Ohne Y, et al
    Oxidised IL-33 drives COPD epithelial pathogenesis via ST2-independent RAGE/EGFR signalling complex.
    Eur Respir J. 2023;62:2202210.
    PubMed     Abstract available
    
    
    August 2023
61. VON BULOW A, Hansen S, Sandin P, Ernstsson O, et al
    Severe asthma trajectories in adults: findings from the NORDSTAR cohort.
    Eur Respir J. 2023 Aug 24:2202474. doi: 10.1183/13993003.02474-2022.
    PubMed     Abstract available
    
    
    
62. POWELL WT, Reeves SR
    From small to big, using microRNA profiling to investigate infant origins of childhood asthma.
    Eur Respir J. 2023;62:2301052.
    PubMed    
    
    
    
63. BRACKE KR, Polverino F
    Blunted adaptive immune responses and acute exacerbations of COPD: breaking the code.
    Eur Respir J. 2023;62:2301030.
    PubMed    
    
    
    
64. CHEN J, Wang X, Schmalen A, Haines S, et al
    Antiviral CD8(+) T-cell immune responses are impaired by cigarette smoke and in COPD.
    Eur Respir J. 2023;62:2201374.
    PubMed     Abstract available
    
    
    
65. LI J, Dell'Aniello S, Ernst P, Suissa S, et al
    Real-world comparative effectiveness of three single-inhaler dual bronchodilators for the treatment of COPD.
    Eur Respir J. 2023;62:2300538.
    PubMed     Abstract available
    
    
    
66. WIJSENBEEK M, Valenzuela C, Holland A
    Palliative care in COPD and ILD: a call for action.
    Eur Respir J. 2023;62:2301076.
    PubMed    
    
    
    
67. CELLI B, Vestbo J
    Simplifying pharmacotherapy for patients with COPD: a viewpoint.
    Eur Respir J. 2023;62:2300115.
    PubMed    
    
    
    
68. OSADNIK CR, Brighton LJ, Burtin C, Cesari M, et al
    European Respiratory Society statement on frailty in adults with chronic lung disease.
    Eur Respir J. 2023;62:2300442.
    PubMed     Abstract available
    
    
    
69. JANSSEN DJA, Bajwah S, Boon MH, Coleman C, et al
    European Respiratory Society clinical practice guideline: palliative care for people with COPD or interstitial lung disease.
    Eur Respir J. 2023;62:2202014.
    PubMed     Abstract available
    
    
    
70. 
    August Podcast: Simplifying pharmacotherapy for patients with COPD.
    Eur Respir J. 2023;62:23E6202.
    PubMed    
    
    
    
71. AMEGADZIE JE, Sadatsafavi M
    A long overdue recognition: COPD as a distinct predictor of cardiovascular disease risk.
    Eur Respir J. 2023;62:2301167.
    PubMed    
    
    
    
72. MACLAGAN LC, Croxford R, Chu A, Sin DD, et al
    Quantifying COPD as a risk factor for cardiac disease in a primary prevention cohort.
    Eur Respir J. 2023;62:2202364.
    PubMed     Abstract available
    
    
    July 2023
73. CAZZOLA M, Page CP, Matera MG, Rogliani P, et al
    Revisiting Asthma Pharmacotherapy: Where Do We Stand and Where Do We Want to Go?
    Eur Respir J. 2023 Jul 20:2300700. doi: 10.1183/13993003.00700-2023.
    PubMed     Abstract available
    
    
    
74. NANZER AM, Taylor V, Hearn AP, Kavanagh JE, et al
    The impact of steroid-sparing biologic therapies on weight loss in obese individuals with severe eosinophilic asthma.
    Eur Respir J. 2023 Jul 20:2300245. doi: 10.1183/13993003.00245-2023.
    PubMed    
    
    
    
75. PICCARI L, Blanco I, Torralba Y, Arismendi E, et al
    Mechanisms of hypoxaemia in severe pulmonary hypertension associated with COPD.
    Eur Respir J. 2023 Jul 6:2300463. doi: 10.1183/13993003.00463-2023.
    PubMed    
    
    
    
76. LEUNG JM, Sin DD
    Predicting steroid responsiveness using airway smooth muscle in COPD: a HISTORIC study.
    Eur Respir J. 2023;62:2300956.
    PubMed    
    
    
    
77. STOLZ D, Papakonstantinou E, Pascarella M, Jahn K, et al
    Airway smooth muscle area to predict steroid responsiveness in COPD patients receiving triple therapy (HISTORIC): a randomised, placebo-controlled, double-blind, investigator-initiated trial.
    Eur Respir J. 2023;62:2300218.
    PubMed     Abstract available
    
    
    
78. 
    July Podcast: The HISTORIC study.
    Eur Respir J. 2023;62:23E6201.
    PubMed    
    
    
    June 2023
79. ZHU Z, Freishtat RJ, Harmon B, Hahn A, et al
    Nasal airway microRNA profiling of infants with severe bronchiolitis and risk of childhood asthma: A multicenter prospective study.
    Eur Respir J. 2023 Jun 15:2300502. doi: 10.1183/13993003.00502-2023.
    PubMed     Abstract available
    
    
    
80. VAN DER VEER T, de Koning Gans JM, Braunstahl GJ, Pieters A, et al
    The effect of beclomethasone-formoterol versus placebo on chronic cough in patients with non-CF bronchiectasis: the FORZA randomised-controlled trial.
    Eur Respir J. 2023 Jun 1:2300186. doi: 10.1183/13993003.00186-2023.
    PubMed    
    
    
    
81. SORIANO JB, Horner A, Studnicka M, Sin DD, et al
    The GOLD 2023 proposed taxonomy: a new tool to determine COPD etiotypes.
    Eur Respir J. 2023;61:2300466.
    PubMed    
    
    
    
82. LEE H, Shin SH, Park HY, Lim SY, et al
    Can we call all obstructive lung diseases COPD?
    Eur Respir J. 2023;61:2300462.
    PubMed    
    
    
    
83. LEUNG V, Lee C
    Shorter duration of antibiotic therapy for exacerbation of COPD.
    Eur Respir J. 2023;61:2300455.
    PubMed    
    
    
    
84. KHAN J, McCarthy C, Franciosi AN
    Questioning the purpose of annual follow-up spirometry for all patients with COPD.
    Eur Respir J. 2023;61:2300292.
    PubMed    
    
    
    
85. AGUSTI A, Anzueto A, Celli BR, Mortimer K, et al
    GOLD 2023 Executive Summary: responses from the GOLD Scientific Committee.
    Eur Respir J. 2023;61:2300616.
    PubMed     Abstract available
    
    
    
86. KIRENGA BJ, Alupo P, van Gemert F, Jones R, et al
    Implication of the Global Initiative for Chronic Obstructive Lung Disease 2023 report for resource-limited settings: tracing the G in the GOLD.
    Eur Respir J. 2023;61:2300484.
    PubMed     Abstract available
    
    
    
87. DUIJTS L
    Prematurity-related chronic respiratory disease across the life course.
    Eur Respir J. 2023;61:2300662.
    PubMed    
    
    
    
88. CHALMERS JD, Aliberti S, Altenburg J, Blasi F, et al
    Transforming clinical research and science in bronchiectasis: EMBARC3, a European Respiratory Society Clinical Research Collaboration.
    Eur Respir J. 2023;61:2300769.
    PubMed    
    
    
    May 2023
89. HERRERO-CORTINA B, Lee AL, Oliveira A, O'Neill B, et al
    European Respiratory Society statement on airway clearance techniques in adults with bronchiectasis.
    Eur Respir J. 2023 May 4:2202053. doi: 10.1183/13993003.02053-2022.
    PubMed     Abstract available
    
    
    
90. SIN DD, Doiron D, Agusti A, Anzueto A, et al
    Air pollution and COPD: GOLD 2023 committee report.
    Eur Respir J. 2023;61:2202469.
    PubMed     Abstract available
    
    
    
91. GOGALI A, Kostikas K
    Latent COPD: a proposed new term in the disease nomenclature.
    Eur Respir J. 2023;61:2300535.
    PubMed    
    
    
    
92. DICKEY BF, Evans CM
    Towards a better mucolytic.
    Eur Respir J. 2023;61:2300619.
    PubMed    
    
    
    
93. ADDANTE A, Raymond W, Gitlin I, Charbit A, et al
    A novel thiol-saccharide mucolytic for the treatment of muco-obstructive lung diseases.
    Eur Respir J. 2023;61:2202022.
    PubMed     Abstract available
    
    
    April 2023
94. EIWEGGER T, Bendien SA
    Defining the questions to be asked in severe asthma trials: data from the COMSA working group.
    Eur Respir J. 2023;61:2202058.
    PubMed    
    
    
    
95. CATALDO D
    COPD pathophysiology: climbing the waterfall of cell death to find a target.
    Eur Respir J. 2023;61:2300093.
    PubMed    
    
    
    
96. MALL MA, Criner GJ, Miravitlles M, Rowe SM, et al
    Cystic fibrosis transmembrane conductance regulator in COPD: a role in respiratory epithelium and beyond.
    Eur Respir J. 2023;61:2201307.
    PubMed     Abstract available
    
    
    
97. AGUSTI A, Celli BR, Criner GJ, Halpin D, et al
    Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary.
    Eur Respir J. 2023;61:2300239.
    PubMed     Abstract available
    
    
    
98. VAN EECKHOUTTE HP, Donovan C, Kim RY, Conlon TM, et al
    RIPK1 kinase-dependent inflammation and cell death contribute to the pathogenesis of COPD.
    Eur Respir J. 2023;61:2201506.
    PubMed     Abstract available
    
    
    
99. ANANTH S, Hurst JR
    ERJ advances: state of the art in definitions and diagnosis of COPD.
    Eur Respir J. 2023;61:2202318.
    PubMed    
    
    
    
100. 
     April Podcast: Global Initiative for Chronic Obstructive Lung Disease 2023 Report.
     Eur Respir J. 2023;61:23E6104.
     PubMed    
     
     
     
101. POLVERINO F, Sciurba F
     Lung volume reduction in COPD: scope or surgery.
     Eur Respir J. 2023;61:2300353.
     PubMed    
     
     
     
102. BUTTERY SC, Banya W, Bilancia R, Boyd E, et al
     Lung volume reduction surgery versus endobronchial valves: a randomised controlled trial.
     Eur Respir J. 2023;61:2202063.
     PubMed     Abstract available
     
     
     March 2023
103. PULAKKA A, Risnes K, Metsala J, Alenius S, et al
     Preterm birth and asthma and COPD in adulthood: a nationwide register study from two Nordic countries.
     Eur Respir J. 2023 Mar 29:2201763. doi: 10.1183/13993003.01763-2022.
     PubMed     Abstract available
     
     
     
104. YANG MJ, Guo SL, Sin DD
     Reply: Association between triple therapy and major adverse cardiovascular events in COPD patients.
     Eur Respir J. 2023;61:2202332.
     PubMed    
     
     
     
105. ALMAGRO P, Martinez-Camblor P
     Comment on: Combination therapy with long-acting bronchodilators and the risk of major adverse cardiovascular events in patients with COPD: a systematic review and meta-analysis.
     Eur Respir J. 2023;61:2202208.
     PubMed    
     
     
     
106. MAHMOUD O, Granell R, Peralta GP, Garcia-Aymerich J, et al
     Early-life and health behaviour influences on lung function in early adulthood.
     Eur Respir J. 2023;61:2001316.
     PubMed     Abstract available
     
     
     
107. CHARRIOT J, Ahmed E, Bourdin A
     Local targeting of TSLP: feat or defeat.
     Eur Respir J. 2023;61:2202389.
     PubMed    
     
     
     
108. SCHNEIDER S, Poglitsch K, Morgenstern C, Quint T, et al
     Dupilumab increases aspirin tolerance in NSAID-exacerbated respiratory disease.
     Eur Respir J. 2023;61:2201335.
     PubMed     Abstract available
     
     
     
109. NOBLE PB, Donovan GM
     If your patient with asthma wheezes when sitting or lying quietly, lung function testing may reveal small airway disease.
     Eur Respir J. 2023;61:2202307.
     PubMed    
     
     
     
110. CORREN J, Brightling CE, Boulet LP, Porsbjerg C, et al
     Not just an anti-eosinophil drug: tezepelumab treatment for type 2 asthma and beyond.
     Eur Respir J. 2023;61:2202202.
     PubMed    
     
     
     
111. BOULET LP, Boulay ME, Cote A, FitzGerald JM, et al
     Airway inflammation and hyperresponsiveness in subjects with respiratory symptoms and normal spirometry.
     Eur Respir J. 2023;61:2201194.
     PubMed     Abstract available
     
     
     February 2023
112. GAUVREAU GM, Hohlfeld JM, FitzGerald MJ, Boulet LP, et al
     Inhaled anti-TSLP antibody fragment, ecleralimab, blocks responses to allergen in mild asthma.
     Eur Respir J. 2023 Feb 23:2201193. doi: 10.1183/13993003.01193-2022.
     PubMed     Abstract available
     
     
     
113. ABDO M, Kirsten AM, von Mutius E, Kopp M, et al
     Minimal Clinically Important Difference for Impulse Oscillometry in Adults with Asthma.
     Eur Respir J. 2023 Feb 9:2201793. doi: 10.1183/13993003.01793-2022.
     PubMed     Abstract available
     
     
     
114. HE ZF, Zha SS, Pan CX, Zhong NS, et al
     Insights into the clinical outcomes of bronchiectasis.
     Eur Respir J. 2023;61:2202104.
     PubMed    
     
     
     
115. DHAR R, Chalmers JD
     Reply to: Insights into the clinical outcomes of bronchiectasis.
     Eur Respir J. 2023;61:2202224.
     PubMed    
     
     
     
116. REGARD L, Burgel PR, Roche N
     Inhaled therapy, cardiovascular risk and benefit-risk considerations in COPD: innocent until proven guilty, or vice versa?
     Eur Respir J. 2023;61:2202135.
     PubMed    
     
     
     
117. SAVOURE M, Bousquet J, Leynaert B, Renuy A, et al
     Rhinitis phenotypes and multimorbidities in the general population: the CONSTANCES cohort.
     Eur Respir J. 2023;61:2200943.
     PubMed     Abstract available
     
     
     
118. YANG M, Li Y, Jiang Y, Guo S, et al
     Combination therapy with long-acting bronchodilators and the risk of major adverse cardiovascular events in patients with COPD: a systematic review and meta-analysis.
     Eur Respir J. 2023;61:2200302.
     PubMed     Abstract available
     
     
     
119. PEDERSEN ESL, Kuehni CE
     Preventing bronchiolitis among infants with non-pharmaceutical interventions outside pandemics: is it realistic?
     Eur Respir J. 2023;61:2202214.
     PubMed    
     
     
     
120. LENGLART L, Ouldali N, Honeyford K, Bognar Z, et al
     Respective roles of non-pharmaceutical interventions in bronchiolitis outbreaks: an interrupted time-series analysis based on a multinational surveillance system.
     Eur Respir J. 2023;61:2201172.
     PubMed     Abstract available
     
     
     January 2023
121. GAO YH, Zheng HZ, Lu HW, Li YY, et al
     The impact of depression and anxiety on the risk of exacerbation in adults with bronchiectasis: A prospective cohort study.
     Eur Respir J. 2023 Jan 20:2201695. doi: 10.1183/13993003.01695-2022.
     PubMed    
     
     
     
122. POLLOCK J, Chalmers JD
     Aspergillus sensitisation: an underappreciated treatable trait in airway disease.
     Eur Respir J. 2023;61:2202042.
     PubMed    
     
     
     
123. FAWCETT KA
     Seeing the trees for the wood: reducing heterogeneity in genomic studies of asthma.
     Eur Respir J. 2023;61:2201931.
     PubMed    
     
     
     
124. BROWN JS, Hurst JR
     Bronchiectasis in low- and middle-income countries: the importance of the wider view.
     Eur Respir J. 2023;61:2201977.
     PubMed    
     
     
     
125. RATANACHINA J, Amaral AFS, De Matteis S, Lawin H, et al
     Association of respiratory symptoms and lung function with occupation in the multinational Burden of Obstructive Lung Disease (BOLD) study.
     Eur Respir J. 2023;61:2200469.
     PubMed     Abstract available
     
     
     
126. MILLER MR, Stanojevic S, Kaminsky DA, Thompson BR, et al
     A reply to questions raised about FEV(1)Q and bronchodilator responsiveness.
     Eur Respir J. 2023;61:2202025.
     PubMed     Abstract available
     
     
     
127. GUAN WJ, Hu PC, Martinez-Garcia MA
     The transcriptomic landscape of diffuse radiological bronchiectasis.
     Eur Respir J. 2023;61:2201733.
     PubMed    
     
     
     December 2022
128. DAVIES D, Hyland ME, Lanario JW, Jones RC, et al
     Moving towards patient-centred outcomes: the Severe Asthma Questionnaire.
     Eur Respir J. 2022 Dec 30:2202305. doi: 10.1183/13993003.02305-2022.
     PubMed    
     
     
     
129. RATTU A, Khaleva E, Brightling C, Dahlen SE, et al
     Identifying and appraising outcome measures for severe asthma: a systematic review.
     Eur Respir J. 2022 Dec 22:2201231. doi: 10.1183/13993003.01231-2022.
     PubMed     Abstract available
     
     
     
130. KOCKS J, van der Molen T, Voorham J, Baldi S, et al
     Development of a tool to detect small airways dysfunction in asthma clinical practice.
     Eur Respir J. 2022 Dec 14:2200558. doi: 10.1183/13993003.00558-2022.
     PubMed     Abstract available
     
     
     
131. HAHN DL, Webley W
     U-BIOPRED/BIOAIR proteins: inflammation or infection?
     Eur Respir J. 2022;60:2200571.
     PubMed    
     
     
     
132. SPARREMAN MIKUS M, Kolmert J, Andersson LI, Dahlen SE, et al
     Reply: U-BIOPRED/BIOAIR proteins: inflammation or infection?
     Eur Respir J. 2022;60:2201795.
     PubMed    
     
     
     
133. LUCZKA-MAJERUS E, Bonnomet A, Germain A, Lalun N, et al
     Ciliogenesis is intrinsically altered in COPD small airways.
     Eur Respir J. 2022;60:2200791.
     PubMed     Abstract available
     
     
     
134. MENZIES-GOW A, Gurnell M, Heaney LG, Corren J, et al
     Adrenal function recovery after durable oral corticosteroid sparing with benralizumab in the PONENTE study.
     Eur Respir J. 2022;60:2103226.
     PubMed     Abstract available
     
     
     November 2022
135. CHERIAN M, Magner KMA, Whitmore GA, Vandemheen KL, et al
     Patient and physician factors associated with symptomatic undiagnosed asthma or COPD.
     Eur Respir J. 2022 Nov 3. pii: 13993003.01721-2022.
     PubMed     Abstract available
     
     
     
136. BUSSE WW
     Improving systemic corticosteroid stewardship in asthma.
     Eur Respir J. 2022;60.
     PubMed    
     
     
     
137. PARK JS, Cho YJ, Yun JY, Lee HJ, et al
     Leukotriene receptor antagonists and risk of neuropsychiatric events in children, adolescents and young adults: a self-controlled case series.
     Eur Respir J. 2022;60.
     PubMed     Abstract available
     
     
     
138. PETSKY H
     Randomised controlled trials utilising F ENO to manage asthma: is it time to acknowledge that "one size does not fit all"?
     Eur Respir J. 2022;60.
     PubMed    
     
     
     
139. ROBERTS G
     Is it time to consider allergen immunotherapy earlier in the management of allergic asthma?
     Eur Respir J. 2022;60.
     PubMed    
     
     
     
140. MENDY A, Merianos AL, Mersha TB, Mahabee-Gittens EM, et al
     Blood volatile organic compounds associated with non-reversible and reversible airflow obstruction in US adults.
     Eur Respir J. 2022;60:2201185.
     PubMed    
     
     
     October 2022
141. XU K, Diaz AA, Duan F, Lee M, et al
     Bronchial Gene Expression Alterations Associated with Radiographic Bronchiectasis.
     Eur Respir J. 2022 Oct 13. pii: 13993003.00120-2022.
     PubMed     Abstract available
     
     
     
142. DHAR R, Singh S, Talwar D, Bv MM, et al
     Clinical outcomes of bronchiectasis in India; Data from the EMBARC/Respiratory Research Network of India registry.
     Eur Respir J. 2022 Oct 13. pii: 13993003.00611-2022.
     PubMed     Abstract available
     
     
     
143. KHALEVA E, Rattu A, Brightling C, Bush A, et al
     Development of Core Outcome Measures sets for paediatric and adult Severe Asthma (COMSA).
     Eur Respir J. 2022 Oct 13. pii: 13993003.00606-2022.
     PubMed     Abstract available
     
     
     
144. POLVERINO F, Marin JM
     The lower respiratory tract: the hot spot for chronic fixed airflow limitation.
     Eur Respir J. 2022;60.
     PubMed    
     
     
     
145. ROMEI C, Castellana R, Conti B, Bemi P, et al
     Quantitative texture-based analysis of pulmonary parenchymal features on chest CT: comparison with densitometric indices and short-term effect of changes in smoking habit.
     Eur Respir J. 2022;60.
     PubMed     Abstract available
     
     
     
146. HILLER AM, Ekstrom M, Piitulainen E, Lindberg A, et al
     Cancer risk in severe alpha-1-antitrypsin deficiency.
     Eur Respir J. 2022;60.
     PubMed     Abstract available
     
     
     September 2022
147. PERSSON C
     Creola bodies and pathogenesis of childhood asthma.
     Eur Respir J. 2022 Sep 30. pii: 13993003.01204-2022.
     PubMed    
     
     
     
148. COLEMAN C, Khaleva E, Rattu A, Frankemolle B, et al
     Narrative Review to capture patients' perceptions and opinions about non-response and response to biological therapy for severe asthma.
     Eur Respir J. 2022 Sep 14. pii: 13993003.00837-2022.
     PubMed     Abstract available
     
     
     
149. LIU J, Bowatte G, Pham J, Perret JL, et al
     Pre-pubertal smoke exposure of fathers and increased risk of offspring asthma: a possible transgenerational effect.
     Eur Respir J. 2022 Sep 14. pii: 13993003.00257-2022.
     PubMed    
     
     
     
150. SORIANO JB
     Planetary respiratory health for asthma, rhinoconjunctivitis and eczema.
     Eur Respir J. 2022;60.
     PubMed    
     
     
     
151. CHAN JSK, Murray RB, Price D
     Oral corticosteroids in asthma and beyond: moving forward.
     Eur Respir J. 2022;60.
     PubMed    
     
     
     
152. ZHANG J, Xu H, Qiao D, DeMeo DL, et al
     A polygenic risk score and age of diagnosis of COPD.
     Eur Respir J. 2022;60.
     PubMed     Abstract available
     
     
     
153. PERREM L, Subbarao P
     Moving the dial on identifying endotypes of asthma from early life.
     Eur Respir J. 2022;60.
     PubMed    
     
     
     
154. 
     "Crucial role for lung iron level and regulation in the pathogenesis and severity of asthma." M.K. Ali, R.Y. Kim, A.C. Brown et al. Eur Respir J 2020; 55: 1901340.
     Eur Respir J. 2022;60.
     PubMed    
     
     
     
155. PAVORD ID
     Case-finding and diagnosis of obstructive airway diseases: the Dragons' Den experience.
     Eur Respir J. 2022;60.
     PubMed    
     
     
     
156. BONADIES L, Papi A, Baraldi E
     Is bronchopulmonary dysplasia in adult age a novel COPD endotype?
     Eur Respir J. 2022;60.
     PubMed    
     
     
     
157. UM-BERGSTROM P, Pourbazargan M, Brundin B, Strom M, et al
     Increased cytotoxic T-cells in the airways of adults with former bronchopulmonary dysplasia.
     Eur Respir J. 2022;60.
     PubMed     Abstract available
     
     
     August 2022
158. CHAN R, Lipworth B
     Interactions between spirometry and oscillometry in patients with moderate to severe asthma.
     Eur Respir J. 2022 Aug 18. pii: 13993003.00543-2022.
     PubMed    
     
     
     
159. LEE S, Prokopenko D, Kelly RS, Lutz S, et al
     Zinc finger protein 33B demonstrates sex-interaction with atopy-related markers in childhood asthma.
     Eur Respir J. 2022 Aug 11. pii: 13993003.00479-2022.
     PubMed     Abstract available
     
     
     
160. TIEW PY, Narayana JK, Li Quek MS, Ang YY, et al
     Sensitisation to recombinant Aspergillus fumigatus allergens and clinical outcomes in COPD.
     Eur Respir J. 2022 Aug 4. pii: 13993003.00507-2022.
     PubMed     Abstract available
     
     
     
161. BURGEL PR, Roche N
     Cystic fibrosis transmembrane conductance regulator (CFTR): a missing link between smoking and chronic airway diseases?
     Eur Respir J. 2022;60.
     PubMed    
     
     
     
162. BONDONNO NP, Parmenter BH, Dalgaard F, Murray K, et al
     Flavonoid intakes inversely associate with COPD in smokers.
     Eur Respir J. 2022;60.
     PubMed     Abstract available
     
     
     
163. SAFERALI A, Qiao D, Kim W, Raraigh K, et al
     C FTR variants are associated with chronic bronchitis in smokers.
     Eur Respir J. 2022;60.
     PubMed     Abstract available
     
     
     
164. SOUTHWORTH T, Jackson N, Singh D
     Airway immune responses to COVID-19 vaccination in COPD patients and healthy subjects.
     Eur Respir J. 2022;60.
     PubMed    
     
     
     
165. PUTMAN RK, Axelsson GT, Ash SY, Sanders JL, et al
     Interstitial lung abnormalities are associated with decreased mean telomere length.
     Eur Respir J. 2022;60.
     PubMed     Abstract available
     
     
     July 2022
166. PERRET JL, Dharmage SC, Bui DS
     Early life respiratory infections and pre-adult asthma: could there be an interaction and differential misclassification?
     Eur Respir J. 2022 Jul 26. pii: 13993003.01141-2022.
     PubMed    
     
     
     
167. MCLOUGHLIN RF, Clark VL, Urroz PD, Gibson PG, et al
     Increasing physical activity in severe asthma: a systematic review and meta-analysis.
     Eur Respir J. 2022 Jul 26. pii: 13993003.00546-2022.
     PubMed     Abstract available
     
     
     
168. VAN MEEL ER, Duijts L
     Reply to: "Early-life respiratory infections and pre-adult asthma: could there be an interaction and differential misclassification?"
     Eur Respir J. 2022 Jul 26. pii: 13993003.01384-2022.
     PubMed    
     
     
     
169. TISI S, Dickson JL, Horst C, Quaife SL, et al
     Detection of COPD in the SUMMIT Study Lung Cancer Screening Cohort using Symptoms and Spirometry.
     Eur Respir J. 2022 Jul 26. pii: 13993003.00795-2022.
     PubMed     Abstract available
     
     
     
170. MURPHY VE, Jensen ME, Holliday EG, Giles WB, et al
     Effect of asthma management with exhaled nitric oxide versus usual care on perinatal outcomes.
     Eur Respir J. 2022 Jul 1. pii: 13993003.00298-2022.
     PubMed     Abstract available
     
     
     
171. REDMOND C, Heaney LG, Chaudhuri R, Jackson DJ, et al
     Benefits of specialist severe asthma management: demographic and geographic disparities.
     Eur Respir J. 2022 Jul 1. pii: 13993003.00660-2022.
     PubMed     Abstract available
     
     
     
172. HOLMES J, McGarvey LP, Birring SS, Fletcher H, et al
     An observational study to determine the relationship between cough frequency and markers of inflammation in severe asthma.
     Eur Respir J. 2022 Jul 1. pii: 13993003.03205-2021.
     PubMed     Abstract available
     
     
     
173. SALTER B, Zhao N, Son K, Suray Tan N, et al
     Airway autoantibodies are determinants of asthma severity.
     Eur Respir J. 2022 Jul 1. pii: 13993003.00442-2022.
     PubMed     Abstract available
     
     
     
174. WURZEL D, Licciardi PV
     Targeted strategies are needed to prevent childhood asthma.
     Eur Respir J. 2022;60.
     PubMed    
     
     
     
175. KAZA N, Lin VY, Stanford D, Hussain SS, et al
     Evaluation of a novel CFTR potentiator in COPD ferrets with acquired CFTR dysfunction.
     Eur Respir J. 2022;60.
     PubMed     Abstract available
     
     
     
176. WARK PAB
     We need to understand why viral infections lead to acute asthma.
     Eur Respir J. 2022;60.
     PubMed    
     
     
     
177. MATTILA T, Erhola M, Vasankari T, Toppila-Salmi S, et al
     Controlling chronic respiratory diseases in Finland from 1996 to 2018.
     Eur Respir J. 2022;60.
     PubMed    
     
     
     
178. VAN HULST G, Jorssen J, Jacobs N, Henket M, et al
     Reply: Ex vivo SOCS3 gene responsiveness to alarmins in eosinophils of mepolizumab-treated patients is as yet of unknown biological significance.
     Eur Respir J. 2022;60.
     PubMed    
     
     
     
179. COUILLARD S
     The alarmin(g) effect of interleukin-5 blockade on residual eosinophil function is of clinical consequence.
     Eur Respir J. 2022;60.
     PubMed    
     
     
     
180. MCINNIS MC, Ma J, Karur GR, Houbois C, et al
     Chronic lung allograft dysfunction phenotype and prognosis by machine learning CT analysis.
     Eur Respir J. 2022;60.
     PubMed     Abstract available
     
     
     June 2022
181. SHOEMARK A, Griffin H, Wheway G, Hogg C, et al
     Genome sequencing reveals underdiagnosis of primary ciliary dyskinesia in bronchiectasis.
     Eur Respir J. 2022 Jun 21. pii: 13993003.00176-2022.
     PubMed     Abstract available
     
     
     
182. CHANG AB, Zacharasiewicz A, Goyal V, Boyd J, et al
     Task Force report: European Respiratory Society statement for defining respiratory exacerbations in children and adolescents with bronchiectasis for clinical trials.
     Eur Respir J. 2022 Jun 21. pii: 13993003.00300-2022.
     PubMed     Abstract available
     
     
     
183. 
     "International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma." Kian Fan Chung, Sally E. Wenzel, Jan L. Brozek, et al. Eur Respir J 2014; 43: 343-373.
     Eur Respir J. 2022;59.
     PubMed    
     
     
     
184. CAZZOLA M, Martinez-Garcia MA, Matera MG
     Bronchodilators in bronchiectasis: there is light but it is still too dim.
     Eur Respir J. 2022;59.
     PubMed    
     
     
     
185. CHANG AB, Boyd J, Bush A, Hill AT, et al
     International consensus statement on quality standards for managing children/adolescents with bronchiectasis from the ERS CRC Child-BEAR-Net.
     Eur Respir J. 2022;59.
     PubMed    
     
     
     
186. YUGE M, Hori S, Ushida K, Momosaki R, et al
     Karaoke as a feasible alternative therapy to pulmonary rehabilitation for COPD.
     Eur Respir J. 2022;59.
     PubMed    
     
     
     
187. LOKKE A, Kaasgaard M, Andreasson KH, Rasmussen DB, et al
     Reply: The effectiveness of singing versus exercise training.
     Eur Respir J. 2022;59.
     PubMed    
     
     
     
188. VAES AW, Spruit MA, Franssen FME, van 't Hul AJ, et al
     The efficacy of singing versus exercise training: do the data really support the authors' conclusions?
     Eur Respir J. 2022;59.
     PubMed    
     
     
     
189. BATEMAN ED, Price DB, Wang HC, Schonffeldt P, et al
     Reply to: Cause or consequence?
     Eur Respir J. 2022;59.
     PubMed    
     
     
     
190. VOLPE FM
     Cause or consequence?
     Eur Respir J. 2022;59.
     PubMed    
     
     
     
191. CHALMERS JD, Aksamit T, Aliberti S, Dhar R, et al
     World Bronchiectasis Day 2022.
     Eur Respir J. 2022;59.
     PubMed    
     
     
     May 2022
192. WOEHLK C, Von Bulow A, Ghanizada M, Baastrup Sondergaard M, et al
     Allergen immunotherapy effectively reduces the risk of exacerbations and lower respiratory tract infections in both seasonal and perennial allergic asthma: a nationwide epidemiological study.
     Eur Respir J. 2022 May 26. pii: 13993003.00446-2022.
     PubMed     Abstract available
     
     
     
193. SUN Y, Zhang M, Ou Z, Meng Y, et al
     Indoor microbiome, microbial and plant metabolites, chemical compounds and asthma symptoms in junior high school students: a multicentre association study in Malaysia.
     Eur Respir J. 2022 May 26. pii: 13993003.00260-2022.
     PubMed     Abstract available
     
     
     
194. HUMBERT M, Bourdin A, Taille C, Kamar D, et al
     Real-life omalizumab exposure and discontinuation in a large nationwide population-based study of pediatric and adult asthmatics.
     Eur Respir J. 2022 May 26. pii: 13993003.03130-2021.
     PubMed     Abstract available
     
     
     
195. HABENER A, Grychtol R, Gaedcke S, DeLuca D, et al
     IgA(+) memory B cells are significantly increased in patients with asthma and small airways dysfunction.
     Eur Respir J. 2022 May 20. pii: 13993003.02130-2021.
     PubMed     Abstract available
     
     
     
196. KROES JA, Zielhuis SW, De Jong K, Hashimoto S, et al
     Cumulative Corticosteroid Sparing Effect of Anti-Interleukin-5/5Ra In Eosinophilic Asthma.
     Eur Respir J. 2022 May 20. pii: 13993003.02983-2021.
     PubMed     Abstract available
     
     
     
197. AZZO L, Ali YS, Vaqar S, Dauriat G, et al
     Severe pulmonary hypertension associated with chronic obstructive pulmonary disease Long-term results of a prospective French multicenter cohort.
     Eur Respir J. 2022 May 20. pii: 13993003.02897-2021.
     PubMed     Abstract available
     
     
     
198. KOEHLER P, von Stillfried S, Garcia Borrega J, Fuchs F, et al
     Aspergillus tracheobronchitis in COVID-19 patients with acute respiratory distress syndrome: a cohort study.
     Eur Respir J. 2022;59.
     PubMed    
     
     
     
199. MATHIOUDAKIS AG, Abroug F, Agusti A, Ananth S, et al
     ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations.
     Eur Respir J. 2022;59.
     PubMed     Abstract available
     
     
     
200. GAIETTO K, Han YY, Forno E, Bacharier LB, et al
     Violence-related distress and lung function in two longitudinal studies of youth.
     Eur Respir J. 2022;59.
     PubMed     Abstract available
     
     
     
201. LATIMER LE, Constantin-Teodosiu D, Popat B, Constantin D, et al
     Whole-body and muscle responses to aerobic exercise training and withdrawal in ageing and COPD.
     Eur Respir J. 2022;59.
     PubMed     Abstract available
     
     
     
202. SORIANO JB, Hopkinson NS
     Sing out for COPD!
     Eur Respir J. 2022;59.
     PubMed    
     
     
     
203. VESTBO J, Waterer G, Leather D, Crim C, et al
     Mortality after admission with pneumonia is higher than after admission with an exacerbation of COPD.
     Eur Respir J. 2022;59.
     PubMed    
     
     
     
204. YUN JH, Lee S, Srinivasa P, Morrow J, et al
     An interferon-inducible signature of airway disease from blood gene expression profiling.
     Eur Respir J. 2022;59.
     PubMed     Abstract available
     
     
     
205. KAASGAARD M, Rasmussen DB, Andreasson KH, Hilberg O, et al
     Use of Singing for Lung Health as an alternative training modality within pulmonary rehabilitation for COPD: a randomised controlled trial.
     Eur Respir J. 2022;59.
     PubMed     Abstract available
     
     
     
206. FAIZ A, van den Berge M
     Quality over quantity: the importance of collecting relevant samples to understand complex diseases.
     Eur Respir J. 2022;59.
     PubMed    
     
     
     
207. HIGHAM A, Beech A, Jackson N, Lea S, et al
     Sputum cell counts in COPD patients who use electronic cigarettes.
     Eur Respir J. 2022;59.
     PubMed    
     
     
     
208. XU F, Vasilescu DM, Kinose D, Tanabe N, et al
     The molecular and cellular mechanisms associated with the destruction of terminal bronchioles in COPD.
     Eur Respir J. 2022;59.
     PubMed     Abstract available
     
     
     April 2022
209. RABE KF, Pavord ID, Castro M, Wechsler ME, et al
     Dupilumab efficacy and safety in patients with asthma and blood eosinophils >/=500 cells.microL(-1).
     Eur Respir J. 2022 Apr 29. pii: 13993003.02577-2021.
     PubMed    
     
     
     
210. VAN MEEL ER, Mensink-Bout SM, den Dekker HT, Ahluwalia TS, et al
     Early-life respiratory tract infections and the risk of school-age lower lung function and asthma: a meta-analysis of 150 000 European children.
     Eur Respir J. 2022 Apr 29. pii: 13993003.02395-2021.
     PubMed     Abstract available
     
     
     
211. MENSINK-BOUT SM, van Meel ER, de Jongste JC, Annesi-Maesano I, et al
     Maternal diet in pregnancy and child's respiratory outcomes: an individual participant data meta-analysis of 18 000 children.
     Eur Respir J. 2022;59.
     PubMed     Abstract available
     
     
     
212. SKRONSKA-WASEK W, Durlanik S, Le HQ, Schroeder V, et al
     The antimicrobial peptide S100A8/A9 produced by airway epithelium functions as a potent and direct regulator of macrophage phenotype and function.
     Eur Respir J. 2022;59.
     PubMed     Abstract available
     
     
     
213. SINGH D, Beier J, Astbury C, Belvisi MG, et al
     The novel bronchodilator navafenterol: a phase 2a, multicentre, randomised, double-blind, placebo-controlled crossover trial in COPD.
     Eur Respir J. 2022;59.
     PubMed     Abstract available
     
     
     March 2022
214. THOMAS D, McDonald VM, Pavord ID, Gibson PG, et al
     Asthma remission- what is it and how can it be achieved?
     Eur Respir J. 2022 Mar 31. pii: 13993003.02583-2021.
     PubMed     Abstract available
     
     
     
215. SCHILDKNECHT K, Winthrop KL, Prevots DR, Blakney R, et al
     Nontuberculous mycobacterial pulmonary disease incidence among elderly patients with bronchiectasis.
     Eur Respir J. 2022 Mar 31. pii: 13993003.00018-2022.
     PubMed    
     
     
     
216. HUYNH C, Whitmore GA, Vandemheen KL, FitzGerald JM, et al
     Derivation and Validation of the UCAP-Q Case-finding Questionnaire to Detect Undiagnosed Asthma and COPD.
     Eur Respir J. 2022 Mar 24. pii: 13993003.03243-2021.
     PubMed     Abstract available
     
     
     
217. HAN YY, Yan Q, Chen W, Celedon JC, et al
     Child maltreatment, anxiety and depression, and asthma among British adults in the UK Biobank.
     Eur Respir J. 2022 Mar 17. pii: 13993003.03160-2021.
     PubMed     Abstract available
     
     
     
218. BAL C, Idzko M, Skrgat S, Koch A, et al
     FeNO is associated with disease burden in the German Asthma Net severe asthma cohort.
     Eur Respir J. 2022 Mar 10. pii: 13993003.01233-2021.
     PubMed    
     
     
     
219. KLEIN DK, Silberbrandt A, Frossing L, Hvidtfeldt M, et al
     Impact of former smoking exposure on airway eosinophilic activation and autoimmunity in patients with severe asthma.
     Eur Respir J. 2022 Mar 2. pii: 13993003.02446-2021.
     PubMed     Abstract available
     
     
     
220. VONK JM, Roukema J
     Air pollution susceptibility in children with asthma and obesity: tidal volume as key player?
     Eur Respir J. 2022;59.
     PubMed    
     
     
     
221. POLVERINO F
     Adaptive immune responses and protein homeostasis in COPD: the immunoproteasome.
     Eur Respir J. 2022;59.
     PubMed    
     
     
     
222. THAMRIN C, Robinson PD, Farah CS, King GG, et al
     Technical standards for respiratory oscillometry and bronchodilator response cut-offs.
     Eur Respir J. 2022;59.
     PubMed    
     
     
     
223. KAMMERL IE, Hardy S, Flexeder C, Urmann A, et al
     Activation of immune cell proteasomes in peripheral blood of smokers and COPD patients: implications for therapy.
     Eur Respir J. 2022;59.
     PubMed     Abstract available
     
     
     
224. DAGHER R, Kumar V, Copenhaver AM, Gallagher S, et al
     Novel mechanisms of action contributing to benralizumab's potent anti-eosinophilic activity.
     Eur Respir J. 2022;59.
     PubMed     Abstract available
     
     
     February 2022
225. MAISON N, Omony J, Illi S, Thiele D, et al
     T-high asthma phenotypes across life span.
     Eur Respir J. 2022 Feb 24. pii: 13993003.02288-2021.
     PubMed     Abstract available
     
     
     
226. ALI GB, Lowe AJ, Perret JL, Walters EH, et al
     Impact of lifetime body mass index trajectories on the incidence and persistence of adult asthma.
     Eur Respir J. 2022 Feb 24. pii: 13993003.02286-2021.
     PubMed     Abstract available
     
     
     
227. MORTIMER K, Reddel HK, Pitrez PM, Bateman ED, et al
     Asthma management in low- and middle-income countries: case for change.
     Eur Respir J. 2022 Feb 24. pii: 13993003.03179-2021.
     PubMed     Abstract available
     
     
     
228. MORTIMER K, Lesosky M, Garcia-Marcos L, Innes Asher M, et al
     The burden of asthma, hay fever and eczema in adults in 17 countries: GAN Phase I study.
     Eur Respir J. 2022 Feb 24. pii: 13993003.02865-2021.
     PubMed     Abstract available
     
     
     
229. MOSLEMI A, Kontogianni K, Brock J, Wood S, et al
     Differentiating COPD and Asthma using Quantitative CT Imaging and Machine Learning.
     Eur Respir J. 2022 Feb 24. pii: 13993003.03078-2021.
     PubMed     Abstract available
     
     
     
230. LOUIS R, Satia I, Ojanguren I, Schleich F, et al
     European Respiratory Society Guidelines for the Diagnosis of Asthma in Adults.
     Eur Respir J. 2022 Feb 15. pii: 13993003.01585-2021.
     PubMed     Abstract available
     
     
     
231. SKOV IR, Madsen H, Henriksen DP, Andersen JH, et al
     Low dose oral corticosteroids in asthma associates with increased morbidity and mortality.
     Eur Respir J. 2022 Feb 10. pii: 13993003.03054-2021.
     PubMed     Abstract available
     
     
     
232. TAYTARD J, Koskas M, Beydon N
     Spirometry forced expiratory time is driven by airflow limitation in asthmatic children.
     Eur Respir J. 2022 Feb 10. pii: 13993003.02620-2021.
     PubMed    
     
     
     
233. GARCIA-MARCOS L, Innes Asher M, Pearce N, Ellwood E, et al
     The burden of asthma, hay fever and eczema in children in 25 countries: GAN Phase I study.
     Eur Respir J. 2022 Feb 10. pii: 13993003.02866-2021.
     PubMed     Abstract available
     
     
     
234. MARCON A, Locatelli F, Accordini S
     The coexistence of asthma and COPD: some considerations about prevalence and lung function decline.
     Eur Respir J. 2022 Feb 3. pii: 13993003.00096-2022.
     PubMed    
     
     
     
235. KEARNS N, Bruce P, Williams M, Doppen M, et al
     Repeated dose budesonide/formoterol compared to salbutamol in adult asthma: A randomised cross-over trial.
     Eur Respir J. 2022 Feb 3. pii: 13993003.02309-2021.
     PubMed     Abstract available
     
     
     
236. SEYS SF, Long MB
     The quest for biomarkers in asthma: challenging the T2 versus non-T2 paradigm.
     Eur Respir J. 2022;59.
     PubMed    
     
     
     
237. ZHANG PD, Zhang XR, Zhang A, Li ZH, et al
     Associations of genetic risk and smoking with incident COPD.
     Eur Respir J. 2022;59.
     PubMed     Abstract available
     
     
     
238. FRANCIOSI AN, Fraughen D, Carroll TP, McElvaney NG, et al
     Alpha-1 antitrypsin deficiency: clarifying the role of the putative protective threshold.
     Eur Respir J. 2022;59.
     PubMed     Abstract available
     
     
     January 2022
239. PARASKAKIS E, Sarikloglou E, Fouzas S, Steiropoulos P, et al
     Improved prediction of asthma exacerbations by measuring distal airway inflammation.
     Eur Respir J. 2022 Jan 27. pii: 13993003.01684-2021.
     PubMed    
     
     
     
240. GAUVREAU GM, Davis BE, Scadding G, Boulet LP, et al
     Allergen Provocation Tests in Respiratory Research: Building on 50 Years of Experience.
     Eur Respir J. 2022 Jan 27. pii: 13993003.02782-2021.
     PubMed     Abstract available
     
     
     
241. RICCARDI D, Ward JP, Yarova PL, Janssen LJ, et al
     Topical therapy with negative allosteric modulators of the calcium-sensing receptor (calcilytics) for the management of asthma: the beginning of a new era?
     Eur Respir J. 2022 Jan 20. pii: 13993003.02103-2021.
     PubMed     Abstract available
     
     
     
242. AL-SHAIKHLY T, Murphy RC, Parker A, Lai Y, et al
     Location of eosinophils in the airway wall is critical for specific features of airway hyperresponsiveness and T2 inflammation in asthma.
     Eur Respir J. 2022 Jan 13. pii: 13993003.01865-2021.
     PubMed     Abstract available
     
     
     
243. PEROTIN JM, Wheway G, Tariq K, Azim A, et al
     Vulnerability to acid reflux of the airway epithelium in severe asthma.
     Eur Respir J. 2022 Jan 7. pii: 13993003.01634-2021.
     PubMed     Abstract available
     
     
     
244. RAMIS J, Middlewick R, Pappalardo F, Cairns JT, et al
     Lysyl oxidase-like 2 is increased in asthma and contributes to asthmatic airway remodelling.
     Eur Respir J. 2022 Jan 7. pii: 13993003.04361-2020.
     PubMed     Abstract available
     
     
     
245. COLAK Y, Lange P
     Interpreting blood eosinophil counts in health and obstructive lung disease.
     Eur Respir J. 2022;59.
     PubMed    
     
     
     
246. BENSON VS, Hartl S, Barnes N, Galwey N, et al
     Blood eosinophil counts in the general population and airways disease: a comprehensive review and meta-analysis.
     Eur Respir J. 2022;59.
     PubMed     Abstract available
     
     
     December 2021
247. RAITA Y, Perez-Losada M, Freishtat RJ, Hahn A, et al
     Nasopharyngeal metatranscriptome profiles of infants with bronchiolitis and risk of childhood asthma: a multicentre prospective study.
     Eur Respir J. 2021 Dec 16. pii: 13993003.02293-2021.
     PubMed     Abstract available
     
     
     
248. PORSBJERG C, Nieto-Fontarigo JJ, Cerps S, Ramu S, et al
     Phenotype and severity of asthma determines bronchial epithelial immune responses to a viral mimic.
     Eur Respir J. 2021 Dec 16. pii: 13993003.02333-2021.
     PubMed     Abstract available
     
     
     
249. AGARWAL R, Muthu V
     Prednisolone plus itraconazole in acute-stage allergic bronchopulmonary aspergillosis complicating asthma.
     Eur Respir J. 2021 Dec 9. pii: 13993003.02989-2021.
     PubMed    
     
     
     
250. HAVETTE A, Regard L, Roche N, Burgel PR, et al
     Prednisolone plus itraconazole in acute-stage allergic bronchopulmonary aspergillosis complicating asthma: is the benefit worth the risk?
     Eur Respir J. 2021 Dec 9. pii: 13993003.02924-2021.
     PubMed    
     
     
     
251. KRUIZINGA MD, Essers E, Stuurman FE, Yavuz Y, et al
     Clinical validation of digital biomarkers for pediatric patients with asthma and cystic fibrosis - Potential for clinical trials and clinical care.
     Eur Respir J. 2021 Dec 9. pii: 13993003.00208-2021.
     PubMed     Abstract available
     
     
     
252. GURDENIZ G, Ernst M, Rago D, Kim M, et al
     Neonatal metabolome of cesarean section and risk of childhood asthma.
     Eur Respir J. 2021 Dec 9. pii: 13993003.02406-2021.
     PubMed     Abstract available
     
     
     
253. RYAN D, Sabroe I
     Identifying and addressing health inequalities in asthma care.
     Eur Respir J. 2021;58.
     PubMed    
     
     
     
254. PAPAIOANNOU AI, Photiades A, Gaga M
     Using placebo-controlled trials to define predictors of future exacerbations in severe asthma patients.
     Eur Respir J. 2021;58.
     PubMed    
     
     
     
255. CHALMERS JD, Keir HR
     Less is more? Antibiotic treatment duration for exacerbations of bronchiectasis.
     Eur Respir J. 2021;58.
     PubMed    
     
     
     
256. KURODA N, Shiroshita A, Tsujimoto Y
     Room for methodological improvement in gait speed study for COPD patients.
     Eur Respir J. 2021;58.
     PubMed    
     
     
     
257. WALSH JA, Barker RE, Kon SSC, Jones SE, et al
     Reply to: Room for methodological improvement in gait speed study for COPD patients.
     Eur Respir J. 2021;58.
     PubMed    
     
     
     
258. LIU S, Lim YH, Pedersen M, Jorgensen JT, et al
     Long-term air pollution and road traffic noise exposure and COPD: the Danish Nurse Cohort.
     Eur Respir J. 2021;58.
     PubMed     Abstract available
     
     
     
259. HERNANDEZ CORDERO AI, Yang CX, Milne S, Li X, et al
     Epigenetic blood biomarkers of ageing and mortality in COPD.
     Eur Respir J. 2021;58.
     PubMed    
     
     
     
260. BEDI P, Cartlidge MK, Zhang Y, Turnbull K, et al
     Feasibility of shortening intravenous antibiotic therapy for bronchiectasis based on bacterial load: a proof-of-concept randomised controlled trial.
     Eur Respir J. 2021;58.
     PubMed     Abstract available
     
     
     
261. PARK S, Lee S, Kim Y, Cho S, et al
     Kidney function and obstructive lung disease: a bidirectional Mendelian randomisation study.
     Eur Respir J. 2021;58.
     PubMed     Abstract available
     
     
     November 2021
262. ABDEL-AZIZ MI, Vijverberg SJH, Neerincx AH, Brinkman P, et al
     A multi-omics approach to delineate sputum microbiome-associated asthma inflammatory phenotypes.
     Eur Respir J. 2021 Nov 25. pii: 13993003.02603-2021.
     PubMed    
     
     
     
263. REINKE SN, Naz S, Chaleckis R, Gallart-Ayala H, et al
     Urinary metabotype of severe asthma evidences decreased carnitine metabolism independent of oral corticosteroid treatment in the U-BIOPRED study.
     Eur Respir J. 2021 Nov 25. pii: 13993003.01733-2021.
     PubMed     Abstract available
     
     
     
264. JAYARAM L, Vandal AC, Chang C, Lewis C, et al
     Tiotropium treatment for bronchiectasis: a randomised, placebo-controlled, crossover trial.
     Eur Respir J. 2021 Nov 18. pii: 13993003.02184-2021.
     PubMed     Abstract available
     
     
     
265. MIKUS MS, Kolmert J, Andersson LI, Ostling J, et al
     Plasma proteins elevated in severe asthma despite oral steroid use and unrelated to Type-2 inflammation.
     Eur Respir J. 2021 Nov 4. pii: 13993003.00142-2021.
     PubMed     Abstract available
     
     
     
266. STRIDSMAN C, Vanfleteren LEGW, Konradsen JR, Axelsson Fisk S, et al
     Predictors of severe COVID-19 in a registry-based Swedish cohort of patients with COPD.
     Eur Respir J. 2021;58.
     PubMed    
     
     
     
267. OLIVER BG
     Food for thought: why is there more airway smooth muscle in asthma?
     Eur Respir J. 2021;58.
     PubMed    
     
     
     
268. MANNINO DM
     Asthma, COPD and their overlap: coexistence or something more?
     Eur Respir J. 2021;58.
     PubMed    
     
     
     
269. WALSH JA, Barker RE, Kon SSC, Jones SE, et al
     Gait speed and adverse outcomes following hospitalised exacerbation of COPD.
     Eur Respir J. 2021;58.
     PubMed     Abstract available
     
     
     
270. FINNEGAN SL, Harrison OK, Harmer CJ, Herigstad M, et al
     Breathlessness in COPD: linking symptom clusters with brain activity.
     Eur Respir J. 2021;58.
     PubMed     Abstract available
     
     
     October 2021
271. PIJNENBURG MW, Frey U, De Jongste JC, Saglani S, et al
     Childhood asthma- pathogenesis and phenotypes.
     Eur Respir J. 2021 Oct 28. pii: 13993003.00731-2021.
     PubMed     Abstract available
     
     
     
272. ELSEY L, Pantin T, Holmes LJ, Tavernier G, et al
     Outcomes over the first two years of treatment with mepolizumab in severe asthma.
     Eur Respir J. 2021 Oct 28. pii: 13993003.01313-2021.
     PubMed     Abstract available
     
     
     
273. SIBILA O, Laserna E, Shoemark A, Perea L, et al
     Heterogeneity of treatment response in bronchiectasis clinical trials.
     Eur Respir J. 2021 Oct 21. pii: 13993003.00777-2021.
     PubMed     Abstract available
     
     
     
274. REDDEL HK, Bacharier LB, Bateman ED, Brightling CE, et al
     Global Initiative for Asthma (GINA) Strategy 2021 - Executive summary and rationale for key changes.
     Eur Respir J. 2021 Oct 19. pii: 13993003.02730-2021.
     PubMed     Abstract available
     
     
     
275. CHAN R, Misirovs R, Lipworth B
     Repeatability of impulse oscillometry in patients with severe asthma.
     Eur Respir J. 2021 Oct 8. pii: 13993003.01679-2021.
     PubMed    
     
     
     
276. SUN Y, Xia PF, Xie J, Mustieles V, et al
     Association of blood trihalomethane concentrations with asthma in U.S. adolescents: nationally representative cross-sectional study.
     Eur Respir J. 2021 Oct 8. pii: 13993003.01440-2021.
     PubMed     Abstract available
     
     
     
277. PORSBJERG C, Maitland-van der Zee AH, Brusselle G, Canonica GW, et al
     3TR: a pan-European cross-disease research consortium aimed at improving personalised biological treatment of asthma and COPD.
     Eur Respir J. 2021;58.
     PubMed    
     
     
     
278. CHANG AB, Boyd J, Bush A, Grimwood K, et al
     Children's Bronchiectasis Education Advocacy and Research Network (Child-BEAR-Net): an ERS Clinical Research Collaboration on improving outcomes of children and adolescents with bronchiectasis.
     Eur Respir J. 2021;58.
     PubMed    
     
     
     
279. KEIR HR, Chalmers JD
     IL-6 trans-signalling: how Haemophilus surfs the NET to amplify inflammation in COPD.
     Eur Respir J. 2021;58.
     PubMed    
     
     
     
280. PETOUSI N, Wooden A, Russell REK
     A new piece in the puzzle: the eosinophil and the development of COPD.
     Eur Respir J. 2021;58.
     PubMed    
     
     
     
281. WINSLOW S, Odqvist L, Diver S, Riise R, et al
     Multi-omics links IL-6 trans-signalling with neutrophil extracellular trap formation and Haemophilus infection in COPD.
     Eur Respir J. 2021;58.
     PubMed     Abstract available
     
     
     
282. PHILIP J, Collins A, Smallwood N, Chang YK, et al
     Referral criteria to palliative care for patients with respiratory disease: a systematic review.
     Eur Respir J. 2021;58.
     PubMed     Abstract available
     
     
     
283. PARK HY, Chang Y, Kang D, Hong YS, et al
     Blood eosinophil counts and the development of obstructive lung disease: the Kangbuk Samsung Health Study.
     Eur Respir J. 2021;58.
     PubMed     Abstract available
     
     
     
284. HIRAI K, Tanaka A, Sato H, Sato Y, et al
     Effect of surgical mask on exercise capacity in COPD: a randomised crossover trial.
     Eur Respir J. 2021;58.
     PubMed    
     
     
     September 2021
285. MIURA S, Iwamoto H, Omori K, Yamaguchi K, et al
     Accelerated decline in lung function in adults with a history of remitted childhood asthma.
     Eur Respir J. 2021 Sep 29. pii: 13993003.00305-2021.
     PubMed     Abstract available
     
     
     
286. BATEMAN ED, Price DB, Wang HC, Khattab A, et al
     Short-acting beta2-agonist prescriptions are associated with poor clinical outcomes of asthma: the multi-country, cross-sectional SABINA III study.
     Eur Respir J. 2021 Sep 24. pii: 13993003.01402-2021.
     PubMed     Abstract available
     
     
     
287. BUSBY J, Matthews JG, Chaudhuri R, Pavord ID, et al
     Factors affecting adherence with treatment advice in a clinical trial of patients with severe asthma.
     Eur Respir J. 2021 Sep 24. pii: 13993003.00768-2021.
     PubMed     Abstract available
     
     
     
288. PANAGOU P, Tzilas V, Bouros D
     "Dynamic (C dyn) lung compliance in non-smokers with asthma and fixed, non-reversible airflow obstruction" ERJ 2021 58: 2004400.
     Eur Respir J. 2021 Sep 24. pii: 13993003.02361-2021.
     PubMed    
     
     
     
289. GREDIC M, Wu CY, Hadzic S, Pak O, et al
     Myeloid cell-specific deletion of inducible nitric oxide synthase protects against smoke-induced pulmonary hypertension in mice.
     Eur Respir J. 2021 Sep 2. pii: 13993003.01153-2021.
     PubMed     Abstract available
     
     
     
290. LOUIS R, Louis G, Bonhomme O
     NOVELTY: a landmark study in phenotyping and endotyping chronic obstructive airway diseases in real clinical practice.
     Eur Respir J. 2021;58.
     PubMed    
     
     
     
291. BAFADHEL M, Barnes N, Bourke SC, Compton C, et al
     A single blood eosinophil count measurement is as good as two for prediction of ICS treatment response in the IMPACT trial.
     Eur Respir J. 2021;58.
     PubMed    
     
     

Thank you for your interest in scientific medicine.

AMEDEO Obstructive Lung Diseases is free of charge.